Lv62
2364 积分 2025-03-04 加入
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
17天前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
1个月前
已完结
Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
2个月前
已完结
Osimertinib with Chemotherapy in EGFR -Mutated NSCLC
2个月前
已关闭
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
2个月前
已完结
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study
3个月前
已完结
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
4个月前
已完结
Cannabinoid Interactions with Cytochrome P450 Drug Metabolism: a Full-Spectrum Characterization
4个月前
已完结
Phase I and Pharmacokinetic Study of LU79553, a DNA Intercalating Bisnaphthalimide, in Patients With Solid Malignancies
5个月前
已完结
195 Avelumab internalization and lysosomal degradation by circulating immune cells in human is mediated by both Fc gamma Receptor (FcgR) and PD-L1 binding
5个月前
已完结
皖公网安备34019202002308
